Loading…
Nuvalent, Inc. is projected to rise to $121.95 by 2027, a +14% move from its current price of $107.38. NUVL is currently trading above its 50-day average (a bullish sign). Technical indicators currently lean strong buy.
A data-driven summary — not financial advice. See the full breakdown below.
Live market data via Yahoo Finance · updated 5/28/2026
| Period | Min | Prediction | Max | Change |
|---|---|---|---|---|
| May 29 | $105.65 | $107.38 | $109.14 | 0.00% |
| May 30 | $104.95 | $107.39 | $109.88 | +0.01% |
| May 31 | $104.41 | $107.39 | $110.45 | +0.01% |
| Jun 1 | $103.96 | $107.39 | $110.94 | +0.01% |
| Jun 2 | $103.56 | $107.39 | $111.36 | +0.01% |
| Jun 3 | $103.21 | $107.40 | $111.75 | +0.02% |
| Jun 4 | $102.88 | $107.40 | $112.11 | +0.02% |
| Period | Min | Prediction | Max | Change |
|---|---|---|---|---|
| Week 1 | $102.88 | $107.40 | $112.11 | +0.02% |
| Week 2 | $101.09 | $107.42 | $114.15 | +0.04% |
| Week 3 | $99.73 | $107.44 | $115.74 | +0.05% |
| Week 4 | $98.61 | $107.46 | $117.10 | +0.07% |
| Week 5 | $97.63 | $107.48 | $118.31 | +0.09% |
| Week 6 | $96.76 | $107.50 | $119.43 | +0.11% |
| Week 7 | $95.97 | $107.52 | $120.46 | +0.13% |
Short-term targets derived from the forecast trend and recent volatility. Highly uncertain — not financial advice.
Nuvalent, Inc. is a clinical-stage biopharmaceutical company focused on developing therapies for cancer. Its lead product candidates are Zidesamtinib (NVL-520), a novel ROS1-selective inhibitor to address the clinical challenges of emergent treatment resistance, CNS-related adverse events, and brain metastases in ROS1-positive NSCLC, which is in Phase 2 of the ARROS-1 Phase 1/2 trial; Neladalkib (NVL-655), a brain-penetrant ALK-selective inhibitor to address resistance, CNS adverse events, and brain metastases that may limit the use of ALK inhibitors, in Phase 2 of the ALKOVE-1 trial; and NVL-330, a brain-penetrant HER2-selective inhibitor designed to treat tumors driven by HER2ex20, with brain metastases and off-target EGFR concerns, in Phase 1a/1b.
Nuvalent has a strategic partnership with Guardant Health, Inc. to develop companion diagnostics therapies. The company was incorporated in 2017 and is headquartered in Cambridge, Massachusetts.
Nuvalent, Inc. (NUVL) is a clinical-stage biotechnology company focused on cancer therapies and is currently trading with a price of $102.12. The stock operates in the Healthcare sector and is positioned within the mid-cap space.
The current price reflects ongoing clinical programs and development milestones for its pivotal candidates. The company’s near-term price trajectory is shaped by clinical trial progress and partner collaborations that could influence future catalysts.
A major floor 11.7% below — a decisive break under it would weaken the trend.
The nearest floor, 7.8% below — buyers have tended to step in here.
Price is pressing into resistance (1.4% away) — a breakout level to watch.
A major ceiling 7.0% above — clearing it would confirm fresh momentum.
Key NUVL support and resistance from recent price action — levels where the trend has historically paused or reversed. Percentages are the distance from the current price.
A snapshot of NUVL market posture derived from its technical indicators and recent volatility. Higher trend and alignment lean bullish; higher risk means larger swings.
Technical Analysis
Indicators computed on daily closing prices.
| Period | SMA | Action | EMA | Action |
|---|---|---|---|---|
| MA 5 | $103.60 | Buy | $104.40 | Buy |
| MA 10 | $103.08 | Buy | $103.56 | Buy |
| MA 20 | $102.62 | Buy | $103.27 | Buy |
| MA 50 | $102.44 | Buy | $102.88 | Buy |
| MA 100 | $102.66 | Buy | $101.61 | Buy |
| MA 200 | $96.95 | Buy | $97.42 | Buy |
| Name | Value | Action |
|---|---|---|
| RSI (14) | 59.05 | Neutral |
| Stoch RSI (14) | 100.00 | Sell |
| CCI (20) | 179.14 | Buy |
| Williams %R (14) | 0.00 | Info |
| MACD (12,26,9) | 0.32 | Buy |
| ROC (12) | 1.99 | Buy |
| Bollinger %B (20,2) | 1.04 | Sell |
| Stochastic %K (14) | 100.00 | Sell |
| TRIX (15) | -0.01 | Sell |
| Awesome (5,34) | -0.14 | Sell |
| Ultimate (7,14,28) | 64.31 | Neutral |
| Momentum (10) | 4.84 | Buy |
| Aroon Osc (25) | -28.00 | Sell |
| Hull MA (9) | 104.82 | Buy |
| ADX (14) | 9.40 | Neutral |
| ATR (14) | 1.79 | Info |
In the near term, the technical picture is bullish. RSI 14 is 50, indicating neutral momentum, while sentiment is listed as BULLISH. The stock is hovering around the 50-day moving average at $102.15, above the 200-day moving average of $96.62, suggesting a constructive baseline.
Support is at $99.04 and resistance at $108.85, with a 30-day range of $92.15 to $113.17.
| Year | Min | Avg | Max | ROI | Sentiment |
|---|---|---|---|---|---|
| $94.77 | $107.38 | $146.80 | 0% | Neutral | |
| $99.63 | $121.95 | $156.26 | +14% | Neutral | |
| $114.20 | $142.35 | $187.16 | +33% | Bullish | |
| $131.83 | $166.80 | $223.87 | +55% | Bullish | |
| $153.05 | $196.24 | $268.04 | +83% | Bullish | |
| $173.53 | $225.18 | $312.36 | +110% | Bullish | |
| $178.21 | $233.85 | $328.94 | +118% | Bullish | |
| $189.99 | $251.91 | $358.90 | +135% | Bullish | |
| $203.97 | $273.11 | $393.71 | +154% | Bullish | |
| $209.83 | $283.61 | $413.36 | +164% | Bullish | |
| $310.76 | $438.01 | $668.80 | +308% | Bullish | |
| $637.95 | $964.21 | $1,577.70 | +798% | Bullish |
Current year — the forecast is anchored to the live price, so ROI shows 0%.
| Month | Min | Avg | Max | Change |
|---|---|---|---|---|
| May 2026 | $94.77 | $107.38 | $125.30 | +0.00% |
| June 2026 | $90.31 | $105.35 | $125.28 | -1.89% |
| July 2026 | $91.74 | $107.63 | $129.21 | +2.17% |
| August 2026 | $94.37 | $111.22 | $134.49 | +3.33% |
| September 2026 | $94.38 | $111.64 | $135.79 | +0.37% |
| October 2026 | $95.17 | $112.97 | $138.15 | +1.19% |
| November 2026 | $98.47 | $117.24 | $144.05 | +3.78% |
| December 2026 | $99.63 | $118.95 | $146.80 | +1.46% |
Click any year to see its month-by-month NUVL forecast. Min / Avg / Max are a bear / base / bull scenario; ROI is the projected move from the current price. Change is the month-over-month move in the average. Estimates, not guarantees.
By 2026, NUVL could reach as high as $146.80, with a base case around $107.38 and support toward $94.77 — roughly 0% from $107.38. Price action looks broadly range-bound.
Expect NUVL to range from $99.63 to $156.26 through 2027. The $121.95 average target implies a +14% move from current prices. That is up +14% on the projected 2026 average. A consolidation phase looks the most probable path here.
The NUVL price prediction for 2028 points to an average of $142.35 (low $114.20, high $187.16) — a potential gain of +33% on today's $107.38. Momentum favours further upside here.
In 2029, NUVL is projected to trade between $131.83 and $223.87, averaging $166.80 — a potential gain of +55% from today's $107.38. That is up +17% on the projected 2028 average. Buyers look set to stay in control over this stretch.
Nuvalent, Inc.'s 2030 outlook centres on $196.24, within a $153.05 to $268.04 range. That is up +18% on the projected 2029 average. That marks a +83% change versus current levels. Momentum favours further upside here.
By 2031, NUVL could reach as high as $312.36, with a base case around $225.18 and support toward $173.53 — roughly +110% from $107.38. Buyers look set to stay in control over this stretch.
Expect NUVL to range from $178.21 to $328.94 through 2032. The $233.85 average target implies a +118% move from current prices. That is up +4% on the projected 2031 average. Momentum favours further upside here.
The NUVL price prediction for 2033 points to an average of $251.91 (low $189.99, high $358.90) — a potential gain of +135% on today's $107.38. Buyers look set to stay in control over this stretch.
In 2034, NUVL is projected to trade between $203.97 and $393.71, averaging $273.11 — a potential gain of +154% from today's $107.38. That is up +8% on the projected 2033 average. Momentum favours further upside here.
Nuvalent, Inc.'s 2035 outlook centres on $283.61, within a $209.83 to $413.36 range. That is up +4% on the projected 2034 average. That marks a +164% change versus current levels. Buyers look set to stay in control over this stretch.
By 2040, NUVL could reach as high as $668.80, with a base case around $438.01 and support toward $310.76 — roughly +308% from $107.38. Momentum favours further upside here.
Expect NUVL to range from $637.95 to $1,577.70 through 2050. The $964.21 average target implies a +798% move from current prices. That is up +120% on the projected 2040 average. Buyers look set to stay in control over this stretch.
Investing $1,000 in NUVL today (≈ 9.312721 NUVL) could be worth
$8,979.39
+$7,979.39 (+798%) by 2050 · US Dollar
Based on the average projected NUVL price of $964.21 in 2050.
Based on the base (average) forecast scenario. FX rates are indicative. Estimates only — not financial advice.
See what a past investment in NUVLwould be worth at today's price.
$1,000 invested in NUVL on May 27, 2025 (≈ 13.837001 NUVL) would be worth
$1,485.82
+$485.82 (+48.6%) today · 1.49× · US Dollar
Based on a NUVL entry price of $72.27 vs. today's $107.38.
| Invested | Entry price | Value today | Return |
|---|---|---|---|
| 1 week ago | $102.32 | $1,049.45 | +4.9% |
| 1 month ago | $104.04 | $1,032.1 | +3.2% |
| 3 months ago | $103.93 | $1,033.2 | +3.3% |
| 6 months ago | $109.35 | $981.98 | -1.8% |
| 1 year ago | $72.27 | $1,485.82 | +48.6% |
| All time (4.8y) ago | $18.75 | $5,726.93 | +472.7% |
Past performance from historical market data — it does not predict future results. FX rates are indicative. Not financial advice.
Enter a price to see how it sits against our NUVL forecast.
Our base-case forecast reaches $210.00 around 2031.
Implied market cap at $210.00: $15.45B
The multi-year forecast shows substantial upside. By 2026 the avg is $102.12 with 0% ROI, rising to a 2027 avg of $115.80 (13.4% ROI), 2028 avg $136.05 (33.2% ROI), and 2029 avg $158.62 (55.3% ROI). By 2030 the avg is $186.36 (82.5% ROI), 2031 $214.61 (110.2%), and 2032 $221.64 (117%).
The path continues to 2033 with an avg of $239.26 (134.3%), 2034 at $260.32 (154.9%), and 2035 at $267.93 (162.4%). In 2040 the avg is $417.55 (308.9% ROI) and by 2050 the avg reaches $911.81 (792.9% ROI). Drivers include Nuvalent’s lead programs in Phase 2 and its Guardant Health collaboration, though outcomes depend on trial results and regulatory decisions.
These figures are estimates, not guarantees, and real-world results may differ.
Tap a question to reveal the answer.
Avg price $186.36; min $145.32; max $254.61; ROI 82.5%; sentiment BULLISH.
The forecast shows significant long-term upside with Avg prices rising from $102.12 in 2026 to $186.36 in 2030 and $911.81 by 2050, with ROI rising to 792.9% by 2050; note that 2026 begins with 0% ROI.
Yes. The 2028 forecast lists an Avg of $136.05 and a max of $178.94, indicating the potential to exceed $150 within that year.
Current price is $102.12 and market cap is $8.07B.
RSI14 is 50; SMA50 is $102.15; SMA200 is $96.62; support is $99.04; resistance is $108.85; 30-day range is $92.15 to $113.17.
Nuvalent, Inc. Community Discussion
0Share your Nuvalent, Inc. price prediction and read what the community thinks. Be respectful — comments are public and not financial advice.
Be the first to share your prediction…
What's your take? Add a comment above to start the conversation.